The Ottawa Regional Cancer Centre
Welcome,         Profile    Billing    Logout  
 4 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Morgan, Scott
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2478
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
NRG-GU013, NCT05946213: Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Recruiting
3
1209
Canada, US
External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
NRG Oncology, National Cancer Institute (NCI)
Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
03/36
03/41
CYTOSHRINK, NCT04090710: SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

Active, not recruiting
2
66
Canada, RoW
Ipilimumab/ Nivolumab, Yervoy/Opdivo, SBRT + Ipilimumab/Nivolumab
Ontario Clinical Oncology Group (OCOG), Bristol-Myers Squibb
Metastatic Renal Cell Carcinoma
03/24
03/25
DEFINE, NCT05851547: Dose Escalation For INtraprostatic LEsions

Recruiting
2
54
Canada
Prostate SBRT with Focal Boost, Ultrahypofractionated prostate radiotherapy with integrated microboost, Triptorelin Injection, Androgen Deprivation Therapy
Ottawa Hospital Research Institute, Knight Therapeutics (USA) Inc
Prostatic Neoplasms
06/27
06/28
PLATON, NCT03784755: Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer

Recruiting
N/A
410
Canada
Ablative Radiation Therapy, SBRT, Stereotactic External Beam Irradiation, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, Standard of care
Canadian Cancer Trials Group, Canadian Cancer Society (CCS)
Prostate Cancer Metastatic
12/26
07/27
Lalani, Aly-Khan
RADIANT, NCT04543110: Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

Recruiting
2
16
Canada
Durvalumab, (MEDI4736), Immune Modulating Radiation, Neoadjuvant Immune Modulating Radiation
Ottawa Hospital Research Institute, Cross Cancer Institute, Hamilton Health Sciences Corporation, London Health Sciences Centre, Ontario Institute for Cancer Research, AstraZeneca, Ozmosis Research Inc.
Bladder Cancer
10/23
11/24
CYTOSHRINK, NCT04090710: SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

Active, not recruiting
2
66
Canada, RoW
Ipilimumab/ Nivolumab, Yervoy/Opdivo, SBRT + Ipilimumab/Nivolumab
Ontario Clinical Oncology Group (OCOG), Bristol-Myers Squibb
Metastatic Renal Cell Carcinoma
03/24
03/25
Hutt, Amy
CYTOSHRINK, NCT04090710: SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

Active, not recruiting
2
66
Canada, RoW
Ipilimumab/ Nivolumab, Yervoy/Opdivo, SBRT + Ipilimumab/Nivolumab
Ontario Clinical Oncology Group (OCOG), Bristol-Myers Squibb
Metastatic Renal Cell Carcinoma
03/24
03/25

Download Options